Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024.
- ET
CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024. - Zevra has seen a meaningful increase in reimbursement coverage, reaching nearly 75% of covered lives as of May 1, 2024.
- Overview of Q1 2024 Financial Results:
Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. - ET, to discuss its corporate and financial results for Q1 2024.